Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

T Dunn

Showing results (381-390 of 392) with videos related to

Pageof 40
Sort By:
Antiviral Therapy|February 17, 2007
A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trialHannah Green, Diana M Gibb, Alexandra Compagnucci, et al.
AIDS (London, England)|April 14, 2010
Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children, K Boyd, David T Dunn, et al.
Trials|March 26, 2016
An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxisDavid I Dolling, Monica Desai, Alan McOwan, et al.
Brain : a Journal of Neurology|December 1, 2025
Immune alterations in schizophrenia and the effects of a therapeutic antibody: a neuroimaging studyYuya Mizuno, Ines Carreira Figueiredo, Toby Pillinger, et al.
Human Molecular Genetics|July 13, 1999
PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndromeD J Marsh, J B Kum, K L Lunetta, et al.
Lancet (London, England)|September 14, 2015
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trialSheena McCormack, David T Dunn, Monica Desai, et al.
Eclinicalmedicine|January 23, 2023
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2Alex J Szubert, Katrina M Pollock, Hannah M Cheeseman, et al.
ACS Medicinal Chemistry Letters|February 21, 2015
An Orally Available BACE1 Inhibitor That Affords Robust CNS Aβ Reduction without Cardiovascular LiabilitiesYuan Cheng, James Brown, Ted C Judd, et al.
Eclinicalmedicine|January 19, 2022
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trialKatrina M Pollock, Hannah M Cheeseman, Alexander J Szubert, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|February 19, 2008
Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the ratMark R Fielden, Alex Nie, Michael McMillian, et al.
Pageof 40

Showing results (381-390 of 392) with videos related to

Sort By:
Pageof 40
Antiviral Therapy|February 17, 2007
A randomized controlled trial of genotypic HIV drug resistance testing in HIV-1-infected children: the PERA (PENTA 8) trialHannah Green, Diana M Gibb, Alexandra Compagnucci, et al.
AIDS (London, England)|April 14, 2010
Discordance between CD4 cell count and CD4 cell percentage: implications for when to start antiretroviral therapy in HIV-1 infected children, K Boyd, David T Dunn, et al.
Trials|March 26, 2016
An analysis of baseline data from the PROUD study: an open-label randomised trial of pre-exposure prophylaxisDavid I Dolling, Monica Desai, Alan McOwan, et al.
Brain : a Journal of Neurology|December 1, 2025
Immune alterations in schizophrenia and the effects of a therapeutic antibody: a neuroimaging studyYuya Mizuno, Ines Carreira Figueiredo, Toby Pillinger, et al.
Human Molecular Genetics|July 13, 1999
PTEN mutation spectrum and genotype-phenotype correlations in Bannayan-Riley-Ruvalcaba syndrome suggest a single entity with Cowden syndromeD J Marsh, J B Kum, K L Lunetta, et al.
Lancet (London, England)|September 14, 2015
Pre-exposure prophylaxis to prevent the acquisition of HIV-1 infection (PROUD): effectiveness results from the pilot phase of a pragmatic open-label randomised trialSheena McCormack, David T Dunn, Monica Desai, et al.
Eclinicalmedicine|January 23, 2023
COVAC1 phase 2a expanded safety and immunogenicity study of a self-amplifying RNA vaccine against SARS-CoV-2Alex J Szubert, Katrina M Pollock, Hannah M Cheeseman, et al.
ACS Medicinal Chemistry Letters|February 21, 2015
An Orally Available BACE1 Inhibitor That Affords Robust CNS Aβ Reduction without Cardiovascular LiabilitiesYuan Cheng, James Brown, Ted C Judd, et al.
Eclinicalmedicine|January 19, 2022
Safety and immunogenicity of a self-amplifying RNA vaccine against COVID-19: COVAC1, a phase I, dose-ranging trialKatrina M Pollock, Hannah M Cheeseman, Alexander J Szubert, et al.
Toxicological Sciences : an Official Journal of the Society of Toxicology|February 19, 2008
Interlaboratory evaluation of genomic signatures for predicting carcinogenicity in the ratMark R Fielden, Alex Nie, Michael McMillian, et al.
Pageof 40